Is the chipmaker — once a master of giving clients what they want — giving away too much?
Illustration by Sam Ward
On a drizzly December morning in Taipei, the most pressing issue in Taiwan’s Legislative Yuan was not the dozens of Chinese military aircraft and vessels that had stalked through the Taiwan Strait the previous weekend, but a new semiconductor factory that was under construction an ocean away.
Inside one of the Yuan’s austere meeting rooms, opposition politician Chiu Chen-yuan grilled foreign minister Joseph Wu about the latest unstoppable expansion of Taiwan Semiconductor Manufactur
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
